Biopsy Devices Market: Key Players, Strategies & Revenue Outlook 2033

Global Biopsy Devices Market Size and Forecast

According to Renub Research Global Biopsy Devices Market is projected to reach US$ 4.02 billion by 2033, increasing from US$ 2.43 billion in 2024, with a CAGR of 5.75% during 2025 to 2033. Market expansion is primarily driven by the rising global incidence of cancer, growing preference for minimally invasive procedures, and increasing adoption of personalized treatment approaches requiring accurate tissue diagnosis. As cancer screening programs expand worldwide, biopsy devices are becoming critical tools in early and precise disease detection.

Biopsy devices play a vital role in diagnosing a wide range of medical conditions, particularly cancer, by enabling tissue extraction for laboratory examination. Technological advancements have resulted in more precise, safer, and patient-friendly biopsy devices. Increasing demand for non-invasive diagnostic procedures, improved healthcare infrastructure, enhanced awareness of early disease detection, and higher investment in oncology research are expected to further strengthen market growth in the coming decade.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=biopsy-devices-market-key-players-analysis-p.php

Global Biopsy Devices Market Key Players Analysis

Biopsy devices are essential medical tools used to extract tissue samples for clinical examination and diagnosis. They are widely utilized in oncology, dermatology, gastroenterology, pulmonology, urology, and other specialties to evaluate abnormal growths, lesions, or suspected tumors. Key biopsy device types include needle biopsy systems, punch biopsy tools, and surgical biopsy instruments.

Needle-based biopsy devices such as fine-needle aspiration and core needle biopsy systems enable minimally invasive tissue sampling with reduced patient discomfort and minimal damage to surrounding tissues. Punch biopsy tools are most commonly used for dermatological sampling, whereas surgical biopsy devices are used when deeper or larger tissue samples are required.

The increasing global burden of cancer, advancements in imaging modalities, growing preference for accurate diagnostic techniques, and development of next-generation biopsy tools have significantly strengthened the role of biopsy devices in modern medicine.

Leading Biopsy Devices Companies and Strategic Profiles

Cardinal Health, Inc.

Established in 1971 and headquartered in the United States, Cardinal Health plays a fundamental role in the biopsy devices industry through its extensive healthcare distribution and medical product portfolio. The company supports hospitals, clinics, and diagnostic centers globally by ensuring reliable access to advanced biopsy instruments. Cardinal Health’s broad logistics capabilities enhance product availability, improving diagnostic efficiency and patient outcomes.

Hologic Inc.

Founded in 1985 and headquartered in the United States, Hologic Inc. specializes in medical imaging, diagnostics, and surgical solutions. The company is particularly renowned for its strong expertise in breast health technologies, including advanced breast biopsy systems and imaging-guided diagnostic solutions. Its comprehensive global presence supports improved cancer screening, particularly among women.

Danaher Corporation

Established in 1984 in the United States, Danaher Corporation is a leading global healthcare technology company with strong contributions to diagnostics, medical research, and life sciences. Through its advanced diagnostic platforms, laboratory automation systems, imaging technologies, and precision instrumentation, Danaher plays an influential role in enhancing biopsy accuracy and laboratory efficiency worldwide.

Becton, Dickinson and Company (BD)

Founded in 1897 and headquartered in the United States, Becton Dickinson (BD) is a prominent player in medical technology. BD’s biopsy solutions include high-precision sampling tools, advanced diagnostic assistance systems, and minimally invasive biopsy instruments. The company’s extensive global manufacturing infrastructure and strong hospital partnerships significantly enhance biopsy accessibility and quality.

Boston Scientific Corporation

Since its establishment in 1979, Boston Scientific has been a leading innovator in interventional medical technologies. The company offers biopsy and diagnostic support technologies across gastroenterology, pulmonology, oncology, and interventional radiology. With manufacturing facilities distributed across multiple countries and a robust distribution network, Boston Scientific plays a key role in advancing biopsy capabilities worldwide.

Medtronic Biopsy Devices Innovation

In April 2024, Medtronic launched its ColonPRO software for the GI Genius intelligent endoscopy platform. This AI-driven innovation enhances real-time detection of colorectal abnormalities, improves diagnostic precision, and facilitates better patient outcomes. Such advancements underline Medtronic’s continued commitment to digital healthcare transformation.

Olympus Corporation Biopsy Devices Product Launch

In October 2025, Olympus introduced SecureFlex, a single-use fine-needle biopsy device primarily designed for pancreatic cancer diagnosis using endoscopic ultrasound guidance. Initially launched across Europe and Japan, it is set to expand globally, demonstrating Olympus’ leadership in gastrointestinal biopsy technology.

SWOT Insights on Key Biopsy Market Players

Cook Medical

Cook Medical remains an innovation leader in biopsy technology with precision-focused products including the EchoTip ClearCore EUS Biopsy Needle, designed for superior tissue sampling quality and procedural flexibility. High physician satisfaction scores reinforce strong clinical confidence and competitive market positioning.

INRAD, Inc.

INRAD’s competitive strength lies in its unique No-Throw biopsy technology, reducing trauma and improving procedural safety. Its PreciseCore technology ensures secure sampling while maintaining clinical precision, strengthening its market presence.

Recent Developments Strengthening the Global Biopsy Devices Market

CONMED Corporation enhanced its market presence by acquiring In2Bones Global Inc., expanding its product and service capabilities.

Argon Medical Devices launched the SuperCore Advantage Semi-Automatic Biopsy Instrument in 2023, offering improved tissue sample volume and diagnostic accuracy.

Sustainability Commitments in the Biopsy Devices Industry

Sustainability is emerging as a strategic focus among leading biopsy device manufacturers.

Stryker Corporation targets carbon neutrality by 2030 and aims for 100% renewable electricity globally by 2027.

B. Braun Melsungen AG plans to reduce Scope 1 and 2 emissions by 50% by 2030, adopting renewable energy systems and eco-efficient manufacturing practices.

Global Biopsy Devices Market Assessment Scope

Comprehensive market evaluation includes historical trend analysis, future revenue forecasts, market share analysis, company benchmarking, strategic SWOT assessments, sustainability performance review, product quality evaluation, innovation pipeline assessment, mergers and acquisitions, partnerships, and investment strategies.

Key Companies Covered in the Global Biopsy Devices Market

Cardinal Health, Inc.

Hologic, Inc.

Danaher Corporation

Becton, Dickinson and Company

Boston Scientific Corporation

Medtronic plc

Olympus Corporation

CONMED Corporation

Argon Medical Devices, Inc.

Cook Medical (Cook Group)

INRAD, Inc.

FUJIFILM Holdings Corporation

Stryker Corporation

Merit Medical Systems, Inc.

B. Braun Melsungen AG

Conclusion

The Global Biopsy Devices Market is advancing steadily, supported by rising cancer incidence, increasing demand for early diagnosis, technological improvements in biopsy procedures, and expanding access to healthcare services. With major companies investing in innovation, sustainability, and global distribution, the biopsy devices market is set for strong and sustained growth through 2033.